Skip to main content

5-Flourouracil Loaded N,O-Carboxymethyl Chitosan Nanoparticles as an Anticancer Nanomedicine for Breast Cancer

Buy Article:

$107.14 + tax (Refund Policy)

Chitosan and its carboxymethyl derivatives are smart biopolymers that are non-toxic, biocompatible, biodegradable and hence found applications in biomedical field. In the current work, we have developed 5-fluorouracil (5-FU) loaded N,O-carboxymethyl chitosan (N,O-CMC) nanoparticles (mean diameter: 80±20 nm, zeta potential: +52.47±2 mV) for cancer drug delivery. Drug entrapment efficiency (65%) and in vitro drug release studies were carried out spectrophotometricaly. Cellular internalization of the drug loaded nanoparticles was confirmed by fluorescent microscopy and flow cytometric analysis. Results of anticancer activity via MTT, apoptosis and caspase 3 assays showed the toxicity of the drug loaded nanoparticles towards breast cancer cells. As a whole these results indicates the potential of 5-FU loaded N,O-CMC nanoparticles in breast cancer chemotherapy in which the side effects of conventional chemo treatment could be reduced. Furthermore, the results of in vitro hemolytic assay and coagulation assay substantiate the blood compatibility of the system as well.

Keywords: 5-FLUOROURACIL; BIOMATERIALS; BREAST CANCER; CANCER DRUG DELIVERY; N,O-CARBOXYMETHYL CHITOSAN; NANOPARTICLES

Document Type: Research Article

Publication date: 01 February 2012

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content